

FORM 7

MONTHLY PROGRESS REPORT

May 2016

Name of CSE Issuer: **True Leaf Medicine International Ltd. (the "*Issuer*").**
Trading Symbol: **MJ**
Number of Outstanding Listed Securities: **52,800,371 common shares**
Date: **June 1, 2016**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On May 13, 2016 the Issuer announced that it had closed a non-brokered private placement by issuing 7,028,404 common shares at a price of \$0.105 per common share for aggregate gross proceeds of \$737,982.42 (the "Private Placement"). The Issuer paid an aggregate cash finder's fee of \$11,723.25 to certain arm's length finders. The amount paid to finders is equal to 7% of the gross proceeds raised from applicable subscriptions in the Private Placement. The Issuer intends to use the proceeds of the Private Placement as follows:

- for working capital to produce inventory and to evaluate potential acquisitions within the pet industry;
- for advertising and marketing costs including digital marketing expenses, creating promotional material and participating in Canadian, US and European trade shows; and
- for the development of new products including research and development, formulation development and conducting pilot trials.

The Issuer also entered into debt conversion agreements with creditors in order to settle \$234,133.56 in outstanding debt through the issuance of 2,229,843 common shares at a deemed price of \$0.105 (the "Debt Conversion"). Pursuant to the Debt Conversion, a director and officer of the Company was issued 1,293,728 common shares of the Company.

In addition, pursuant to the conversion of a previously disclosed loan agreement with First Pacific Enterprises Inc., the Issuer issued 601,843 units at a conversion price of \$0.105 per unit. Each unit is comprised of one common share of the Company and one-half of one share purchase warrant, with each whole warrant being exercisable to purchase an additional common share of the Company at price

of \$0.15 for a period of two years from the date of issuance. The sole shareholder of First Pacific Enterprises Inc. is also a director, shareholder and the Chief Executive Officer of the Issuer.

All securities issued are subject to a hold period under applicable securities laws, which will expire four months and one day from the date of issuance.

2. Provide a general overview and discussion of the activities of management.

See Number 1.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

See Number 1.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

On May 12, 2016 the Issuer issued 7,028,404 Common shares pursuant to the Private Placement at \$0.105 per Common share for total proceeds of \$737,982.42.

On May 12, 2016 the Issuer issued 2,229,843 Common shares pursuant to the Debt Conversion at \$0.105 per Common share settle \$234,133.56 of outstanding debt.

On May 12, 2016 the Issuer issued 601,843 units pursuant to the conversion of a loan agreement. Each unit is comprised of one common share of the Issuer and one-half of one share purchase warrant, each whole warrant is exercisable at \$0.15 for a period of two years from the date of issuance.

15. Provide details of any loans to or by Related Persons.

See number 1.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: June 1, 2016.

Kevin Bottomley
Name of Director or Senior
Officer

"Kevin Bottomley"
Signature

Director
Official Capacity

Issuer Details		
Name of Issuer: True Leaf Medicine International Ltd.	For Month End May 2016	Date of Report: YYYYMMDD 2016/06/01
Issuer Address: 100 Kalamalka Lake Road, Unit 32		
City/Province/Postal Code: Vernon, BC V1T 9G1	Issuer Fax No.: N/A	Issuer Telephone No. 778.475.5323
Contact Name: Darcy Bomford	Contact Position: Director, President & CEO	Contact Telephone No. 778.475.5323
Contact Email Address: darcy@trueleaf.com	Web Site Address: www.trueleaf.com	